{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:40:59Z","timestamp":1790995259937,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperkalemia rates in renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitor users, and factors associated with treatment interruptions and cessations, have not been explored in a large, population-wide database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RAAS inhibitor users were identified in the linked UK Clinical Practice Research Datalink-Hospital Episodes Statistics data set, 2009\u201315. Treatment interruptions (no active prescription followed by reappearance) and cessations were determined. Hyperkalemia (serum K+&amp;gt;5.5\u2009mmol\/L) rates were calculated and factors associated with interruptions and cessations modeled using time-varying Cox regression, including hyperkalemia (as a time-dependent variable).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 434\u2009027 RAAS inhibitor users, the hyperkalemia rate was 1.30 (95% confidence interval 1.28\u20131.32) per 100 patient-years. Of 73.7% of patients who experienced off-treatment periods, 57.6% experienced interruption only, 7.5% cessation only and 8.6% both. Within 1\u2009year of initiating RAAS inhibitor treatment, approximately one-third of the patients experienced interruption or cessation. Hazard ratios for patients with severe hyperkalemia were 1.10 (10.5\u20131.16) for interruptions and 3.37 (3.25\u20133.50) for cessation. Compared with no chronic kidney disease (CKD), risk of interruption was 1.20 (1.16\u20131.25) and 1.57 (1.44\u20131.72) for Stages 4 and 5, respectively, and of cessation was 2.20 (2.07\u20132.33) and 2.87 (2.56\u20133.22). Risk of interruption increased for patients with heart failure or diabetes [1.04 (1.02\u20131.05); 1.13 (1.12\u20131.14), respectively] but the risk of cessation decreased [0.85 (0.82\u20130.87); 0.92 (0.90\u20130.94)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risk of RAAS inhibitor interruption and cessation increased as CKD stage progressed. Efforts targeting reasons for interruptions and, especially, cessations, such as hyperkalemia prevention, could decrease off-treatment periods for patients who would otherwise benefit, such as those with CKD, heart failure or diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfz263","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T15:12:25Z","timestamp":1574694745000},"page":"826-839","source":"Crossref","is-referenced-by-count":39,"title":["Risk of hyperkalemia from renin\u2013angiotensin\u2013aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population"],"prefix":"10.1093","volume":"36","author":[{"given":"James B","family":"Wetmore","sequence":"first","affiliation":[{"name":"Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA"},{"name":"Division of Nephrology, Hennepin Healthcare, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Yan","sequence":"additional","affiliation":[{"name":"Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Horne","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[{"name":"Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Gilbertson","sequence":"additional","affiliation":[{"name":"Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2021042619273112800_gfz263-B1","first-page":"I70","article-title":"Electrolyte abnormalities underlying lethal and ventricular arrhythmias","volume":"85","author":"Gettes","year":"1992","journal-title":"Circulation"},{"key":"2021042619273112800_gfz263-B2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10557-018-6783-0","article-title":"Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies","volume":"32","author":"Hoppe","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2021042619273112800_gfz263-B3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3909\/ricm0727","article-title":"Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management","volume":"15","author":"McCullough","year":"2014","journal-title":"Rev Cardiovasc Med"},{"key":"2021042619273112800_gfz263-B4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"2021042619273112800_gfz263-B5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2021042619273112800_gfz263-B6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/pds.2128","article-title":"Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals","volume":"20","author":"Noize","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021042619273112800_gfz263-B7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes","volume":"24","author":"Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2021042619273112800_gfz263-B8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2021042619273112800_gfz263-B9","first-page":"S1","article-title":"Standards of medical care in diabetes - 2017","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"2021042619273112800_gfz263-B10","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2021042619273112800_gfz263-B11","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"2021042619273112800_gfz263-B12","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021042619273112800_gfz263-B13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000485645","article-title":"Real or perceived: hyperkalemia is a major deterrent for renin-angiotensin aldosterone system inhibition in heart failure","volume":"138","author":"McCullough","year":"2018","journal-title":"Nephron"},{"key":"2021042619273112800_gfz263-B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12882-018-1007-1","article-title":"Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink","volume":"19","author":"Furuland","year":"2018","journal-title":"BMC Nephrol"},{"key":"2021042619273112800_gfz263-B15","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2021042619273112800_gfz263-B16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2021042619273112800_gfz263-B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2021042619273112800_gfz263-B18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2021042619273112800_gfz263-B19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"2021042619273112800_gfz263-B20","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"2021042619273112800_gfz263-B21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2021042619273112800_gfz263-B22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2021042619273112800_gfz263-B23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.14236\/jhi.v24i4.949","article-title":"Research outputs of England's Hospital Episode Statistics (HES) database: bibliometric analysis","volume":"24","author":"Chaudhry","year":"2017","journal-title":"J Innov Health Inform"},{"key":"2021042619273112800_gfz263-B24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2021042619273112800_gfz263-B25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"2021042619273112800_gfz263-B26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pds.1923","article-title":"Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril","volume":"19","author":"Johnson","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021042619273112800_gfz263-B27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1756-0500-6-306","article-title":"Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study","volume":"6","author":"Espinel","year":"2013","journal-title":"BMC Res Notes"},{"key":"2021042619273112800_gfz263-B28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jash.2017.09.011","article-title":"Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension","volume":"11","author":"Kovesdy","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"2021042619273112800_gfz263-B29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11897-017-0341-0","article-title":"Treatment of hyperkalemia in heart failure","volume":"14","author":"DeFilippis","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"2021042619273112800_gfz263-B30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.ackd.2017.06.001","article-title":"Treatment of abnormalities of potassium homeostasis in CKD","volume":"24","author":"Palmer","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2021042619273112800_gfz263-B31","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3909\/ricm17S1S0002","article-title":"Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management","volume":"17 (Suppl 1)","author":"Krishnan","year":"2016","journal-title":"Rev Cardiovasc Med"},{"key":"2021042619273112800_gfz263-B32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"2021042619273112800_gfz263-B33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-150-8-200904210-00005","article-title":"Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage","volume":"150","author":"McWilliams","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021042619273112800_gfz263-B34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ajh\/hps019","article-title":"Impact of race on cumulative exposure to antihypertensive medications in dialysis","volume":"26","author":"Wetmore","year":"2013","journal-title":"Am J Hypertens"},{"key":"2021042619273112800_gfz263-B35","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1681\/ASN.2017020216","article-title":"Understanding medication nonadherence after kidney transplant","volume":"28","author":"Nevins","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021042619273112800_gfz263-B36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jamainternmed.2016.8653","article-title":"Adherence to newly prescribed diabetes medications among insured Latino and White patients with diabetes","volume":"177","author":"Fernandez","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2021042619273112800_gfz263-B37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/jch.13089","article-title":"Disparities in hypertension and cardiovascular disease in blacks: the critical role of medication adherence","volume":"19","author":"Ferdinand","year":"2017","journal-title":"J Clin Hypertens"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/5\/826\/37400361\/gfz263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/5\/826\/37400361\/gfz263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T18:23:00Z","timestamp":1665080580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/5\/826\/5679828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,12,17]]},"published-print":{"date-parts":[[2021,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz263","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2019,12,17]]}}}